PascalFr.i
Checkpoint
PascalFrancis
Racine
Checkpoint
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Checkpoint (PascalFrancis)

Index « PascalFr.i » - entrée « Catechol O-methyltransferase »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Catatonie < Catechol O-methyltransferase < Catechol methyltransferase  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 18.
Ident.Authors (with country if any)Title
000251 (2012) Lonneke M. L. De Lau [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Peter Heutink [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas]Catechol-O-methyltransferase Val158Met and the Risk of Dyskinesias in Parkinson's Disease
000B71 (2010) Jeroen Hoogland [Pays-Bas] ; Rob M. A. De Bie [Pays-Bas] ; Caroline H. Williams-Gray [Royaume-Uni] ; Dino Muslimovic [Pays-Bas] ; Ben Schmand [Pays-Bas] ; Bart Post [Pays-Bas]Catechol-O-methyltransferase Val158Met and Cognitive Function in Parkinson's Disease
001A51 (2006) Thomas Müller [Allemagne] ; Christoph Erdmann [Allemagne] ; Siegfried Muhlack [Allemagne] ; Dirk Bremen [Allemagne] ; Horst Przuntek [Allemagne] ; Dirk Woitalla [Allemagne]Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels
001E40 (2005) Manuela Contin [Italie] ; Paolo Martinelli [Italie] ; Mirella Mochi [Italie] ; Roberto Riva [Italie] ; Fiorenzo Albani [Italie] ; Agostino Baruzzi [Italie]Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease
001F29 (2005) Richard Camicioli [Canada] ; Ali Rajput [Canada] ; Michelle Rajput [Canada] ; Christian Reece [Canada] ; Haydeh Payami [États-Unis] ; CHUNHAI HAO [Canada] ; Alex Rajput [Canada]Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease : Relationship to dementia and hallucinations
002770 (2002) Alexander Fisher [Australie] ; James Croft-Baker [Australie] ; Michael Davis [Australie] ; Patrick Purcell [Australie] ; Allan J. Mclean [Australie]Entacapone-induced hepatotoxicity and hepatic dysfunction
002836 (2002) John L. Goudreau [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Matthew J. Farrer [États-Unis] ; Timothy G. Lesnick [États-Unis] ; Andrew B. Singleton [États-Unis] ; James H. Bower [États-Unis] ; John A. Hardy [États-Unis] ; Walter A. Rocca [États-Unis]Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease
002839 (2002) COMT inhibitors
002919 (2001) William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie]Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
002B70 (2000) Ikuko Mizuta [Japon] ; Eiji Mizuta [Japon] ; Shunzou Yamasaki [Japon] ; Sadako Kuno [Japon] ; Minoru Yasuda [Japon] ; Chikako Tanaka [Japon]Meta-analysis of polymorphism of the catechol-O-methyltransferase gene in relation to the etiology of Parkinson's disease in Japan
002B93 (2000) M. D. Welsh [États-Unis] ; T. Dorflinger [États-Unis] ; D. Chernik [États-Unis] ; C. Waters [États-Unis]Illness Impact and Adjustment to Parkinson's disease : Before and after treatment with tolcapone
002E24 (1999) Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients
003096 (1998) R. A. Hauser [États-Unis] ; E. Molho [États-Unis] ; H. Shale [États-Unis] ; S. Pedder [États-Unis] ; E. E. Dorflinger [États-Unis]A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
003118 (1997) E. Dupont [Danemark] ; J.-M. Burgunder [Suisse] ; L. J. Findley [Royaume-Uni] ; J.-E. Olsson [Suède] ; E. Dorflinger [États-Unis]Tolcapone added to levodopa in stable parkinsonian patients : A double-blind placebo-controlled study
003151 (1997) J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; S. Ahtila [Finlande] ; P. Tuomainen [Finlande] ; H. Ter V Inen [Finlande]Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease
003224 (1997) T. Xie [Hong Kong] ; S. L. Ho [Hong Kong] ; L. S. W. Li [Hong Kong] ; O. C. K. Ma [Hong Kong]G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease
003232 (1997) L. A. Smith [Royaume-Uni] ; A. Gordin [Finlande] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni]Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets
003501 (1995) T. L. Davis [États-Unis] ; M. Roznoski ; R. S. BurnsEffects of tolcapone in Parkinson's patients taking L-dihydroxyphenalalanine/carbidopa and selegiline

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/PascalFr.i -k "Catechol O-methyltransferase" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/PascalFr.i  \
                -Sk "Catechol O-methyltransferase" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Catechol O-methyltransferase
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024